For example, a phase I study in patients with solid tumors such as breast and ovarian cancers, evaluated Emactuzumab, an anti-CSF1R treatment, in combination with paclitaxel chemotherapy (Figure 2B). This evidence concerns the gene CSF1R and ovarian carcinoma.